It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated p-tau217.
Abstract
Plasma phosphorylated tau at threonine 217 (p-tau217) is a robust marker of Alzheimer’s disease (AD) pathology and progression. However, individuals positive for p-tau217 show substantial clinical heterogeneity, suggesting the influence of modifying biological processes. Here, we investigated whether plasma glial fibrillary acidic protein (GFAP) modifies the association between p-tau217 and clinical progression.
We analyzed 3,505 individuals across the aging and AD spectrum from six independent cohorts. All participants had baseline Aβ PET, plasma GFAP, plasma p-tau217, and CDR-SB. Participants were classified into four biomarker groups based on GFAP and p-tau217 positivity. Cross-sectional associations with cognitive severity were examined using linear regression and ANCOVA. Longitudinal cognitive trajectories over five years were modeled using linear mixed-effects models. Variance partitioning decomposed biomarker-attributable variance in individual-level annual CDR-SB change rates. Time to clinical worsening (CDR-SB increase ≥ 0.5 points) was assessed using Kaplan–Meier survival analysis and Cox proportional hazards regression.
We show that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline. Compared to individuals p-tau217-positive-only, individuals with co-elevated GFAP and p-tau217 exhibited worse baseline cognitive performance, faster annual CDR-SB progression (62% higher rate;
p
= 0.008), and an increased hazard of cognitive worsening (HR 1.28; 95% CI 1.01–1.61). The interaction between GFAP and p-tau217 accounted for a large proportion of biomarker-related variance in longitudinal cognitive decline (68.6%), far exceeding the independent contributions of p-tau217 (25.3%) and GFAP (1.1%).
These findings support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated p-tau217, providing additional prognostic stratification within the p-tau217-positive population. Combining plasma GFAP and p-tau217 may therefore have value for identifying individuals at higher risk of progression, with potential implications for risk stratification and clinical trial enrichment.
CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...
J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al.· Molecular Psychiatry· 0 citations
Abstract INTRODUCTION Validation of Alzheimer's disease blood‐based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations between BBMs and quantitative postmortem neuropathology in 124...
Celia R. Bianco, Neus Rabaneda-Lombarte, Hadia A. Fatima et al.· Alzheimer's & Dementia· 0 citations
Higher CSF neuroinflammatory biomarkers may be linked to AD pathology and cognitive impairment; however, given the observational design, causality cannot be established, and longitudinal mechanistic studies are needed to validate these findings.
Mubarak Alruwaili, A. Turkistani, S. Shilbayeh et al.· Immunologic research· 0 citations
Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...
R. Shi, X. Zeng, M. Farinas et al.· medRxiv· 0 citations
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. Brown, A. Weber et al.· medRxiv· 1 citation
Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.
Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al.· Lancet Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.